What is Brief History of Amyris Company?

Amyris Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

What is the history of Amyris?

Amyris, Inc. is a leader in synthetic biotechnology, using engineered microorganisms to create sustainable ingredients. A key early achievement was developing artemisinic acid for an anti-malarial drug, supported by a 2005 grant from the Bill & Melinda Gates Foundation.

Founded in 2003, the company's initial goal was to replace fossil fuels with bio-based alternatives by converting plant sugars into valuable molecules for various industries.

Amyris's journey includes a Chapter 11 bankruptcy filing in August 2023, from which it emerged in May 2024. The company is now concentrating on its core B2B ingredient business, a strategic shift from its previous consumer brand focus. This refocus underscores its dedication to sustainable chemistry and its proprietary strain engineering and fermentation platforms. The company's work in developing ingredients for markets like flavors, fragrances, and cosmetics is notable, as is its contribution to pharmaceuticals through products like artemisinic acid. For a deeper look into the company's operational environment, consider an Amyris PESTEL Analysis.

The Amyris company history began on July 17, 2003, with a vision to transform chemical production through synthetic biology. Founded by a group of scientists from the University of California, Berkeley, including Jack D. Newman, Kinkead Keith Reiling, and Neil Renninger, alongside key figures like Vincent Martin and Jay Keasling, the company aimed to leverage biotechnology for a more sustainable future.

Amyris Founding Story

Amyris was established by visionary scientists from UC Berkeley, driven by a mission to address global reliance on fossil fuels. Their core idea was to engineer microorganisms to produce valuable chemicals and fuels from renewable plant-based sugars.

• Founded on July 17, 2003, by UC Berkeley scientists.
• Key founders include Jack D. Newman, Kinkead Keith Reiling, Neil Renninger, Vincent Martin, and Jay Keasling.
• Initial focus on renewable fuels and chemicals using synthetic biology.
• Pioneered fermentation processes with engineered yeast.

The Amyris founding team recognized the significant environmental impact of traditional chemical synthesis and the global dependence on fossil fuels. Their innovative approach centered on harnessing the power of synthetic biology to create renewable products. The initial business model for Amyris biotechnology involved engineering microorganisms, specifically yeast, to convert plant-derived sugars into high-value compounds through fermentation. This bio-based method was designed to be more efficient and environmentally friendly than conventional chemical manufacturing processes.

A pivotal early achievement for Amyris company history occurred in 2005. With support from a grant from the Bill & Melinda Gates Foundation, the company successfully developed technology to produce artemisinic acid. This compound is a critical precursor for artemisinin, a vital component in effective anti-malarial drugs. This milestone demonstrated the broad potential of Amyris's bio-based approach, extending beyond industrial chemicals to address significant global health challenges. The company, originally known as Amyris Biotechnologies, Inc., officially changed its name to Amyris, Inc. in June 2010, reflecting its evolving scope and ambition. Understanding the Growth Strategy of Amyris provides further insight into its development.

Amyris SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The early history of the Amyris company showcases a dynamic journey of scientific innovation and strategic market shifts. From its origins in biotechnology, the company focused on developing sustainable solutions, marking key milestones in its growth and development.

Pioneering Artemisinic Acid and Public Offering

Amyris made significant strides following the development of its artemisinic acid technology in 2005. By 2008, the company granted royalty-free licenses to Sanofi-Aventis for the production of this anti-malarial precursor. The launch of Biofene, a renewable diesel fuel, marked its first commercial product, and Amyris successfully went public on NASDAQ on September 28, 2010.

Strategic Acquisitions and Manufacturing Expansion

Strategic expansion continued with the acquisition of Draths Corporation in November 2011 for $7 million in stock, bolstering its renewable chemicals capabilities. By 2012, Amyris diversified its offerings to include renewable chemicals like squalane and established its manufacturing presence in Brazil with the Brotas 1 facility. A joint venture, Total Amyris BioSolutions B.V. (TAB), was formed with Total in November 2013 to develop and commercialize Biofene-based fuels.

Pivot to High-Value Markets and Brand Launches

Facing challenges from low petroleum prices, Amyris strategically shifted its focus from fuels to higher-value markets such as flavors, fragrances, and cosmetics. This pivot was highlighted by the launch of its clean beauty brand, Biossance, which began distribution at Sephora in 2017. The company continued to secure capital, including a $34 million private placement in April 2019.

Product Diversification and Technological Advancements

Further product line expansion included the launch of the Pipette baby care line in 2019 and scaling commercial production for Cannabigerol (CBG) in September 2020. During the COVID-19 pandemic, Amyris collaborated with the Infectious Disease Research Institute (IDRI) to advance a novel RNA vaccine platform. A significant manufacturing milestone was achieved in June 2022 with the commencement of precision fermentation at its new facility in Barra Bonita, Brazil. This period of growth and diversification illustrates the Revenue Streams & Business Model of Amyris.

Amyris PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The Amyris company history is a narrative of significant technological advancements and substantial market challenges. Founded with the mission to harness biotechnology for sustainable solutions, the company's journey has been marked by pioneering efforts in synthetic biology, aiming to disrupt traditional chemical production. This path involved navigating complex scientific hurdles and adapting to evolving market demands, as detailed in the Target Market of Amyris.

Synthetic Biology Platform

Amyris's core innovation is its synthetic biology platform, which uses genetically engineered yeast and sugarcane fermentation to produce bio-identical molecules. This technology offers sustainable alternatives to traditional petrochemical-based ingredients.

Lab-to-Market™ Operating System

The company's proprietary Lab-to-Market™ operating system has significantly accelerated product development. It has reduced the average time to market by 80% and product development costs by 90% compared to 2012 levels.

Metabolic Reprogramming

A key breakthrough involved reprogramming central metabolism in its yeast strains. This innovation enhanced product yields, enabling the commercialization of 13 distinct molecules.

Strategic Partnerships

Amyris has leveraged major partnerships to advance its innovation. Collaborations with entities like the Bill & Melinda Gates Foundation for anti-malarial compounds and International Flavors and Fragrances for fragrance molecules highlight its collaborative approach.

Zero-Calorie Sweetener

The company pioneered the production of a zero-calorie, nature-based fermented Reb M sweetener. This product represents a significant advancement in the food and beverage ingredient market.

Renewable Ingredient Manufacturing

Amyris's focus on renewable ingredients for various industries, including beauty and personal care, demonstrates its commitment to sustainable chemistry. This has led to the development of a diverse product portfolio.

The company faced significant challenges, including the initial difficulty in competing with low-cost petroleum in the fuels market. This led to a strategic pivot towards higher-value ingredients and consumer products. Financial strains became evident with total revenues decreasing by over 20% from $341.8 million in 2021 to $269.8 million in 2022, and losses escalating to -$528.51 million in 2022.

Financial Difficulties and Bankruptcy

Substantial financial pressures led to a Chapter 11 bankruptcy filing on August 9, 2023, with liabilities reported between $1 billion and $10 billion. This period also saw the divestment of consumer brands like Biossance and Pipette, and significant layoffs affecting approximately 260 employees.

Market Pivot and Restructuring

The initial ambition to compete in the fuels market proved challenging due to the low cost of petroleum. This necessitated a strategic pivot to higher-value ingredients and consumer products, a move that also presented its own set of market entry and scaling hurdles.

Operational Streamlining

Emerging from bankruptcy in May 2024 under new leadership, the company streamlined operations and reduced costs. This restructuring aimed to refocus on its core B2B sustainable ingredient manufacturing business for a more profitable future.

Delisting and OTC Markets

The company was delisted from Nasdaq and moved to the OTC Markets as part of its financial restructuring. This transition reflected the significant operational and financial adjustments undertaken during the bankruptcy proceedings.

Securing DIP Financing

To navigate the bankruptcy process, Amyris secured $190 million in debtor-in-possession (DIP) financing. This crucial funding provided the necessary capital to continue operations during the restructuring period.

Focus on Core Business

The post-bankruptcy strategy emphasizes a renewed focus on its core B2B sustainable ingredient manufacturing business. This strategic shift aims to leverage its technological strengths in a more targeted and financially sustainable manner.

Amyris Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

The Amyris company history is a narrative of scientific ambition and strategic adaptation, beginning with its founding as Amyris Biotechnologies, Inc. in Emeryville, California, on July 17, 2003. Early milestones included developing technology for artemisinic acid, a precursor for an anti-malarial drug, with support from the Bill & Melinda Gates Foundation. The company went public on September 28, 2010, and has since navigated acquisitions, joint ventures, and significant investments, including a crucial one from the Bill & Melinda Gates Foundation's Strategic Innovation Fund in January 2016. The launch of its clean beauty brand at Sephora in February 2017 marked a significant step into consumer markets, showcasing its Amyris biotechnology capabilities. The company's journey includes scaling commercial production of molecules like CBG and forming strategic partnerships, all while focusing on Amyris renewable ingredients and Amyris sustainable chemicals.

Refined B2B Focus

Following its emergence from bankruptcy in May 2024, the company has sharpened its strategic direction. The approved 2030 Strategic Plan emphasizes a return to core competencies in B2B sustainable ingredient manufacturing.

Financial Recovery and Growth Drivers

As of July 2025, the company reported trailing twelve-month (TTM) earnings of $0.26 Billion USD (Pretax Income). This indicates a positive financial trajectory post-restructuring, supporting its mission to remake the world's chemistry.

Pipeline Expansion and Innovation

The company plans to advance its pipeline of molecules, with stated potential to access over half of all small molecule diversity in nature. Strategic initiatives include developing up to three small molecule drugs for the FDA drug shortage list.

Strategic Operational Adjustments

In November 2024, the company consolidated its R&D operations to the U.S. and Brazil, marking an exit from Portugal. This move aligns with its commitment to efficient operations and achieving its Mission, Vision & Core Values of Amyris.

Amyris Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔